PDI Announces Additional Diagnostic Tests, Shares Off Session Highs Print E-mail
By Josh Gee   
Friday, 14 August 2015 18:20

PDI, Inc. (NASDAQ:PDII) subsidiary Interpace Diagnostics has confirmed that ThyGenX Thyroid Oncogene Panel as well as ThyraMIR are under the ambit of largest independent Blue Cross Blue Shield plans which insures over 3.3 million lives. 

 

This medical policy update is the
first commercial plan which would cover ThyraMIR, a novel microRNA gene expression classifier that was launched earlier in the

Error. Page cannot be displayed. Please contact your service provider for more details. (1)

year.

 

   

Recently, there was coverage by Aetna for ThyGenX, Interpace Diagnostics' genetic mutation panel that was used to for improving risk stratification as well as surgical decision-making when standard cytopathology does not give diagnosis of thyroid cancer. 

   

Together, all plans are a part of 80 million covered lives for Interpace Diagnostics' molecular thyroid diagnostic tests.

   

Interpace Diagnostics' test, Coverage ofPancraGen", was extended to another 1.3 million lives by a contracted top national plan, bringing the

plan's total covered lives for PancraGen to 10 million. 

   

In addition to that, Blue Cross Blue Shield plans renewed PancraGen contract coverage for their 5.9 million lives.

   

The plans show patients having risk of progression to pancreatic cancer as well as others having lower risk with high degree of accuracy by ensuring that members have access to the technology.

     

The combination of all plans represents more than 70 million covered lives for this molecular test.

   

Nancy Lurker, CEO of PDI, Inc, opined that coverage by the additional plan gives more validation of the tests to the members. She added that the firm would advance discussions with more plans for increasing coverage for the tests as well as efforts which would give advantage to patients and help in increasing current growth taking place at Interpace Diagnostics.

   

Shares of the company are down 1% to $2.05 after soaring 35% in early session.

 




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
 
BMR:1